ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL - Slideshow (NYSE:ADCT) 2025-12-03
ADC TherapeuticsADC Therapeutics(US:ADCT) Seeking Alpha·2025-12-03 15:53

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]